Protein Binding of Tolfenamic Acid in the Plasma from Patients with Renal and Hepatic Disease

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1986 Jan 1

PMID 3758148

Citations 3

Authors

M Laznicek

K E Senius

Affiliations

Soon will be listed here.

Abstract

The protein binding of tolfenamic acid in plasma from patients with renal and hepatic disorders was studied by equilibrium dialysis. Drug binding to the cellular components of whole blood and blood cell suspensions was also measured. Salicylic acid was used as the reference drug in all experiments. Renal and hepatic diseases increased the unbound fraction of tolfenamic acid. Free drug fractions were significantly correlated with changes in creatinine, urea, and total bilirubin, but not with those in albumin or total protein in plasma. Comparison of the theoretical binding parameters in control plasma and similar changes in protein binding in all the plasma samples studied revealed that tolfenamic acid and salicylic acid probably share a common primary binding site. The significance of the correlation permits use of salicylic acid as a model drug for predicting changes in the protein binding of tolfenamic acid. The measurements of binding properties in whole blood and blood cell--buffer suspension showed that tolfenamic acid interacts with the lipid membrane structures of blood cells, while salicylic acid is distributed into the aqueous cell space.

Citing Articles

Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.

Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki K, Akizawa H Eur J Drug Metab Pharmacokinet. 2002; 27(1):37-43.

PMID: 11996325 DOI: 10.1007/BF03190403.

Kidney and liver contributions to salicylate metabolism in rats.

Laznicek M, Laznickova A Eur J Drug Metab Pharmacokinet. 1994; 19(1):21-6.

PMID: 7957447 DOI: 10.1007/BF03188818.

Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Zini R, Riant P, Barre J, Tillement J Clin Pharmacokinet. 1990; 19(3):218-29.

PMID: 2203581 DOI: 10.2165/00003088-199019030-00005.

References

Affrime M, Reidenberg M . The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol. 1975; 8(3-4):267-9. DOI: 10.1007/BF00567126. View

WOSILAIT W . Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels. Eur J Clin Pharmacol. 1976; 9(4):285-90. DOI: 10.1007/BF00561662. View

Reidenberg M . Effect of disease states on plasma protein binding of drugs. Med Clin North Am. 1974; 58(5):1103-9. DOI: 10.1016/s0025-7125(16)32106-x. View

Ehrnebo M, AGURELL S, BOREUS L, Gordon E, Lonroth U . Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Ther. 1974; 16(3):424-9. DOI: 10.1002/cpt1974163part1424. View

Williams R, Benet L . Drug pharmacokinetics in cardiac and hepatic disease. Annu Rev Pharmacol Toxicol. 1980; 20:389-413. DOI: 10.1146/annurev.pa.20.040180.002133. View

Linden I, Parantainen J, Vapaatalo H . Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro. Scand J Rheumatol. 1976; 5(3):129-32. DOI: 10.3109/03009747609165450. View

Sudlow G, Birkett D, Wade D . Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976; 12(6):1052-61. View

Erill S, Calvo R, Carlos R . Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharmacol Ther. 1980; 27(5):612-8. DOI: 10.1038/clpt.1980.87. View

Kauppila A, Puolakka J, Ylikorkala O . Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins. 1979; 18(4):655-61. DOI: 10.1016/0090-6980(79)90033-9. View

10.

Borga O, Cederlof I, Ringberger V, Norlin A . Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther. 1976; 20(4):464-75. DOI: 10.1002/cpt1976204464. View

11.

Andreasen F . Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacol Toxicol (Copenh). 1973; 32(6):417-29. DOI: 10.1111/j.1600-0773.1973.tb01488.x. View

12.

Khalifah R, Hignite C, Pentikainen P, Penttila A, Neuvonen P . Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. Eur J Drug Metab Pharmacokinet. 1982; 7(4):269-76. DOI: 10.1007/BF03189629. View

13.

Kajander A, LAINE V, Gothoni G . Effect of tolfenamic acid in rheumatoid arthritis. Scand J Rheumatol. 1972; 1(2):91-3. DOI: 10.3109/03009747209103003. View

14.

REJHOLEC V, Vapaatalo H, Tokola O, Gothoni G . A comparative, double-blind study on tolfenamic acid in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl. 1979; (24):13-6. View

15.

Kajander A, Martio J, Mutru O, Gothoni G . Prolonged treatment with tolfenamic acid in inflammatory rheumatic diseases. Scand J Rheumatol. 1976; 5(3):158-60. DOI: 10.3109/03009747609165455. View

16.

Sudlow G, Birkett D, Wade D . The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975; 11(6):824-32. View

17.

Urien S, Albengres E, Zini R, Tillement J . Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem Pharmacol. 1982; 31(22):3687-9. DOI: 10.1016/0006-2952(82)90597-4. View

18.

Piafsky K . Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980; 5(3):246-62. DOI: 10.2165/00003088-198005030-00004. View

19.

Pentikainen P, Penttila A, Neuvonen P, Khalifah R, Hignite C . Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur J Drug Metab Pharmacokinet. 1982; 7(4):259-67. DOI: 10.1007/BF03189628. View

20.

Wanwimolruk S, Birkett D, Brooks P . Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet. 1982; 7(1):85-92. DOI: 10.2165/00003088-198207010-00005. View